Abstract
Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Anti-Cancer Agents in Medicinal Chemistry
Title: The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy
Volume: 11 Issue: 2
Author(s): Ludmil Benov, James Craik and Ines Batinic-Haberle
Affiliation:
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Abstract: Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Export Options
About this article
Cite this article as:
Benov Ludmil, Craik James and Batinic-Haberle Ines, The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152011795255975
DOI https://dx.doi.org/10.2174/187152011795255975 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Autophagy Regulators as Potential Cancer Therapeutic agents: A Review
Current Topics in Medicinal Chemistry Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets Multi-Modal Imaging and Cancer Therapy Using Lanthanide Oxide Nanoparticles: Current Status and Perspectives
Current Medicinal Chemistry Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Myokines in Myogenesis and Health
Recent Patents on Biotechnology Plant Compounds for the Treatment of Diabetes, a Metabolic Disorder: NF-κB as a Therapeutic Target
Current Pharmaceutical Design